HighVista Strategies’s LENZ Therapeutics LENZ Stock Holding History

HighVista Strategies’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,701	Closed	-$998K	–	125
2021 Q3	$998K	Buy	+8,701	New	+$1.29M	0.66%	54

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighVista Strategies's LENZ Position: Q4 2021 in Review

HighVista Strategies sold out of LENZ Therapeutics (LENZ) in Q4 2021, closing a stake of 8,701 shares — an estimated $998K sold.

HighVista Strategies first reported a position in LENZ in Q3 2021 and held it in 1 quarter. The position peaked at $998K in Q3 2021. 58 funds tracked by Wall St. Rank hold LENZ as of Q4 2021.

HighVista Strategies reported no remaining LENZ Therapeutics position as of Q4 2021 after selling out during the quarter.
HighVista Strategies sold 8,701 LENZ Therapeutics shares in Q4 2021, an estimated $998K.
HighVista Strategies first reported a position in LENZ Therapeutics in Q3 2021 and held it in 1 quarter.
HighVista Strategies's LENZ Therapeutics position peaked at $998K in Q3 2021.
58 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.